一分钟看懂
这是一项关于小细胞肺癌的III 期研究，登记的药物或干预包括obrixtamig；atezolizumab；carboplatin；etoposide，当前状态为招募中。登记地点显示中国北京、蚌埠、长沙、成都等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
obrixtamig；atezolizumab；carboplatin；etoposide · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer Hospital · 北京
- Beijing Chest Hospital, Capital Medical University · 北京
- The First Affiliated Hospital Of Bengbu Medical College · 蚌埠
- Hunan Province Tumor Hospital · 长沙
- Sichuan Cancer Hospital · 成都
- West China Hospital, Sichuan University · 成都
- Fujian Cancer Hospital · 福州
- Sun Yat-Sen University Cancer Center · 广州
- The First Affiliated Hospital,Sun Yat-sen University · 广州
- The First Affiliated Hospital, Zhejiang University · 杭州
- Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine · 杭州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Shandong Cancer Hospital · 济南
- Linyi Cancer Hospital · 临沂
- The First Affiliated Hospital of Nanchang University · 南昌
- The Second Affiliated Hospital to Nanchang University · 南昌
- Nanjing Drum Tower Hospital · 南京
- The Affiliated Cancer Hospital, Guangxi Medical University · 南宁
- The First Affiliated Hospital of Ningbo University · 宁波
- Shanghai Chest Hospital · 上海
- Shanghai Pulmonary Hospital · 上海
- Shanghai Geriatric Medical Center · 上海
- Shanghai General Hospital · 上海
- China Shenyang Chest Hospital · 沈阳
- Shanxi Cancer hospital · 太原
- Tianjin Cancer Hospital · 天津
- The First Affiliated Hospital of Wenzhou Medical University · 温州
- Union Hospital Tongji Medical College Huazhong University of Science and Technology · 武汉
- Xiangyang Central Hospital · 襄阳
- The Affiliated Hospital of Xuzhou Medical College · 徐州
- Northern Jiangsu People's Hospital · 扬州
- Henan Cancer Hospital · 郑州
- The First Affiliated Hospital of Zhengzhou University · 郑州
公开的入选条件
- 1. Patients with histologically confirmed Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- 2. Patients without any previous systemic anti-cancer treatment for ES-SCLC. Patients who received previous systemic anti-cancer treatment during limited stage are eligible if the treatment has been completed more than 6 months before the diagnosis of ES-SCLC.
- 3. Adequate archival formalin-fixed paraffin-embedded (FFPE) tumour tissue, as specified in the Laboratory Manual, must be available for central laboratory analysis of Delta-like ligand 3 (DLL3) expression status and other biomarkers. The central laboratory in
- 4. Patients with asymptomatic brain metastasis are eligible if they meet one of the following criteria:
- Treatment for brain metastases (e.g. whole brain radiation therapy, stereotactic radiotherapy, or radiosurgery) completed at least 7 days prior to randomisation and the patient is neurologically stable without the use of glucocorticoids or therapeutic anti-con
- Untreated brain metastases that do not require treatment and the patient is neurologically stable without the use of glucocorticoids or therapeutic anti-convulsant for at least 28 days prior to randomisation
- 5. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
- 6. Eligible for continuing carboplatin + etoposide + atezolizumab regimen as first-line Standard of care (SoC) treatment within 28 days after the start of the initial cycle of standard therapy
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07472517；登记信息更新于 2026-09-15。